+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

F. Hoffmann-La Roche Ltd - Strategic SWOT Analysis Review

F. Hoffmann-La Roche Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - The analyst’s summarization of the company’s business strategy.
  • SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.

Highlights

F. Hoffmann-La Roche Ltd (Roche) is a biotechnology company and a provider of in-vitro diagnostics as well as a supplier of transformative innovative solutions across major disease areas. It provides drugs for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, healthcare professionals, commercial laboratories, researchers and pharmacists. Roche is headquartered in Basel, Switzerland.

F. Hoffmann-La Roche Ltd Key Recent Developments

  • Jan 30, 2025: Roche Reports Strong 2024 Results With 7% Sales Growth; Fourth Quarter Marks Third Straight Quarter of 9% Growth
  • Jan 30, 2025: F. Hoffmann-La Roche Posts Financial Results for Fiscal 2024
  • Jan 29, 2025: Change to the Roche Enlarged Corporate Executive Committee
  • Jan 02, 2025: Innovent and Roche link on lung cancer therapy development

Reasons to Buy

  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with the analyst’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.

Table of Contents

Section 1 - About the Company
  • F. Hoffmann-La Roche Ltd - Key Facts
  • F. Hoffmann-La Roche Ltd - Key Employees
  • F. Hoffmann-La Roche Ltd - Key Employee Biographies
  • F. Hoffmann-La Roche Ltd - Major Products and Services
  • F. Hoffmann-La Roche Ltd - History
  • F. Hoffmann-La Roche Ltd - Company Statement
  • F. Hoffmann-La Roche Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Affiliate
Section 2 - Company Analysis
  • Company Overview
  • F. Hoffmann-La Roche Ltd - Business Description
  • Business Segment: Diagnostics
  • Overview
  • Performance
  • Business Segment: Pharmaceuticals
  • Overview
  • Performance
  • Geographical Segment: Africa, Australia and Oceania
  • Performance
  • Geographical Segment: Asia
  • Performance
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: Latin America
  • Performance
  • Geographical Segment: North America
  • Performance
  • R&D Overview
  • F. Hoffmann-La Roche Ltd - Corporate Strategy
  • F. Hoffmann-La Roche Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • F. Hoffmann-La Roche Ltd - Strengths
  • F. Hoffmann-La Roche Ltd - Weaknesses
  • F. Hoffmann-La Roche Ltd - Opportunities
  • F. Hoffmann-La Roche Ltd - Threats
  • F. Hoffmann-La Roche Ltd - Key Competitors
Section 3 - Company’s Lifesciences Financial Deals and Alliances
  • F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
  • F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
  • F. Hoffmann-La Roche Ltd, Recent Deals Summary
Section 4 - Company’s Recent Developments
  • Jan 30, 2025: Roche Reports Strong 2024 Results With 7% Sales Growth; Fourth Quarter Marks Third Straight Quarter of 9% Growth
  • Jan 30, 2025: F. Hoffmann-La Roche Posts Financial Results for Fiscal 2024
  • Jan 29, 2025: Change to the Roche Enlarged Corporate Executive Committee
  • Jan 02, 2025: Innovent and Roche link on lung cancer therapy development
  • Dec 04, 2024: Avant Technologies Partner, Ainnova, Signs Pilot Program With Roche to Combat Diabetic Retinopathy
  • Nov 29, 2024: EHA and Roche sign MOU for Egypt’s digital pathology advancement
  • Nov 26, 2024: Roche to acquire Poseida Therapeutics for $1.5bn
  • Oct 23, 2024: F. Hoffmann-La Roche Announces Third Quarter Sales 2024
  • Oct 23, 2024: Roche’s Strong Sales Growth of 9% (Cer) Continues in the Third Quarter of 2024; Group Sales Increase 6% in the First Nine Months
  • Sep 10, 2024: Roche Opens Pharma Research and Development Center in Basel to Accelerate Scientific Innovation
Section 5 - Appendix
  • Methodology
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • F. Hoffmann-La Roche Ltd, Key Facts
  • F. Hoffmann-La Roche Ltd, Key Employees
  • F. Hoffmann-La Roche Ltd, Key Employee Biographies
  • F. Hoffmann-La Roche Ltd, Major Products and Services
  • F. Hoffmann-La Roche Ltd, History
  • F. Hoffmann-La Roche Ltd, Subsidiaries
  • F. Hoffmann-La Roche Ltd, Affiliate
  • F. Hoffmann-La Roche Ltd, Key Competitors
  • F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
  • F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
  • F. Hoffmann-La Roche Ltd, Recent Deals Summary
List of Figures
  • F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
  • F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2019 to YTD 2025

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Viridian Therapeutics Inc
  • Takeda Pharmaceutical Co Ltd
  • Spexis AG
  • Sanofi
  • Pfizer Inc
  • Novo Nordisk AS
  • Novartis AG
  • Merck & Co Inc
  • Medtronic Plc
  • Johnson & Johnson
  • Incyte Corp
  • GSK plc
  • Eli Lilly and Co
  • Danaher Corp
  • Cassava Sciences Inc
  • Bristol-Myers Squibb Co
  • Bio-Rad Laboratories Inc
  • Bayer AG
  • AstraZeneca Plc
  • Astellas Pharma Inc
  • Amgen Inc
  • AbbVie Inc
  • Abbott Laboratories